In this segment, “Recent Developments in Myelofibrosis”, Srdan Verstovsek, MD, PhD and Abdulraheem Yacoub, MD relate clinical experience with ruxolitinib and prospects for the future in myelofibrosis (MF).
Mutation and karyotype-enhanced prognostic models (e.g., MIPPS7+) and better recognition of prefibrotic MF are improving management strategies for individual patients. JAK inhibitors remain center-stage in MF treatment. For ruxolitinib, a substantial body of long-term and real-world data is accumulating since its approval 7 years ago. Second-generation JAK inhibitors and ruxolitinib combinations are major areas of current research.